Theratechnologies downgraded by Leede Jones Gab
$THTX
Biotechnology: Pharmaceutical Preparations
Health Care
Leede Jones Gab downgraded Theratechnologies from Speculative Buy to Hold
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/17/2022 | $9.00 | Overweight | Cantor Fitzgerald |
| 7/29/2021 | $8.00 → $3.00 | Buy → Hold | Canaccord Genuity |
MONTREAL, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, announced today that the Company has obtained the final order from the Superior Court of Québec (Commercial Division) approving the previously-announced plan of arrangement (the "Arrangement") under Chapter XVI – Division II of the Business Corporations Act (Québec) involving CB Biotechnology, LLC (the "Purchaser"), an affiliate of Future Pak, LLC ("Future Pak"). This final court approval follows the approval of the Arrangement by the shareholders of the Company at the special meeting of shareholders held on Septe
MONTREAL, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that its shareholders have approved the previously announced plan of arrangement (the "Arrangement") under Chapter XVI – Division II of the Business Corporations Act (Québec) involving CB Biotechnology, LLC (the "Purchaser"), an affiliate of Future Pak, LLC ("Future Pak"). At the special meeting of shareholders of Theratechnologies held earlier today, the arrangement resolution was approved by 97.44% of the votes cast by the holders of shares present in person or virtually or represented by
EGRIFTA WR™ offers convenience of weekly reconstitution and reduced daily injection volume, compared to EGRIFTA SV® Specialty pharmacies are now ordering EGRIFTA WR™ to fill prescriptions MONTREAL, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, today announced the availability of EGRIFTA WR™ (tesamorelin) for injection for the reduction of excess abdominal fat in adult patients with HIV and lipodystrophy. The announcement follows the approval of EGRIFTA WR™ by the U.S. Food and Drug Administration (FDA) earlier this year. "Excess visceral abdominal fat is an increasin
Cantor Fitzgerald initiated coverage of Theratechnologies with a rating of Overweight and set a new price target of $9.00
Canaccord Genuity downgraded Theratechnologies from Buy to Hold and set a new price target of $3.00 from $8.00 previously
Canaccord Genuity reiterated coverage of Theratechnologies with a rating of Buy and set a new price target of $8.00 from $7.00 previously
6-K - Theratechnologies Inc. (0001512717) (Filer)
6-K - Theratechnologies Inc. (0001512717) (Filer)
6-K - Theratechnologies Inc. (0001512717) (Filer)
SC 13G - Theratechnologies Inc. (0001512717) (Subject)
SC 13G/A - Theratechnologies Inc. (0001512717) (Subject)
SC 13D - Theratechnologies Inc. (0001512717) (Subject)
Q2 2025 total revenue of $17.7 million, and $36.8 million for the first six months of Fiscal 2025Positive Adjusted EBITDA1 for the fifth straight quarterSubsequent to quarter end, Theratechnologies entered into a definitive agreement to be acquired by an affiliate of Future Pak MONTREAL, July 09, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, today reported business highlights and financial results for the second quarter 2025, ended May 31, 2025. All figures are in U.S. dollars unless otherwise stated. "Demand for EGRIFTA SV® remains very strong and we are witnessing
MONTREAL, July 03, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, today announced the Company will report financial results for its second quarter 2025 ended May 31 on Wednesday, July 9, 2025. Given the announcement of July 2, 2025, concerning the acquisition of the Company, a conference call will not be held. About Theratechnologies Theratechnologies (TSX:TH) (NASDAQ:THTX) is a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care. Further information about Theratechnologies is availabl
Offer of US$3.01 in cash plus one contingent value right for potential additional aggregate payments of up to US$1.19 per shareUpfront and total potential cash consideration represent respectively a 126% and 216% premium to Nasdaq closing price on date prior to announcement of Future Pak's initial non-binding proposalTransaction with Future Pak represents culmination of sale process whereby Theratechnologies solicited interest from a number of potential counterpartiesBoard unanimously recommends that shareholders approve the transaction MONTREAL, July 02, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage bio
MONTREAL, April 05, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Elina Tea, Chief Financial Officer at GLS North America, to its Board of Directors and as a member of the Company's Audit Committee. Ms. Tea will be Investissement Québec's designee pursuant to its investor rights agreement with the Company. "Elina Tea's extensive experience in finance, corporate strategy, and investor relations makes her a valuable addition to our Board of Directors," said Dawn Svoronos, Chair of the Board o
MONTREAL, March 21, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Jordan Zwick, Chief Business Officer at Mirador Therapeutics Inc., to its Board of Directors and as a member of the Company's Audit Committee. "We welcome Jordan Zwick to the Board as an important addition to our esteemed group of advisors," said Dawn Svoronos, Chair of the Board of Directors at Theratechnologies. "With his extensive experience in the U.S. biotech and pharmaceutical industry, coupled with expertise in global
MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Mr. Alain Trudeau has resigned from the Board of Directors of Theratechnologies and as a member of its Audit Committee, effective immediately. "I want to thank Alain for his contributions to Theratechnologies as a director since joining the Company in October 2020 and for completing the annual review for the 2023 fiscal year", said Dawn Svoronos, Chair of the Board at Theratechnologies. "Alain was the current Chair of the Audit Committee